Prediction of anthracycline cardiotoxicity after chemotherapy by biomarkers kinetic analysis

Cardiovascular Toxicology

Volumn 12, Issue 2, 2012, Pages 135-142

  Garrone, Ornella ^a   Crosetto, Nicola ^b   Nigro, Cristiana Lo ^a   Catzeddu, Tiziana ^a   Vivenza, Daniela ^a   Monteverde, Martino ^a   Merlano, Marco ^a   Feola, Mauro ^c  

^a S CROCE E CARLE HOSPITAL   (Italy)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c Ospedale 4   (Italy)

Author keywords

Anthracycline cardiotoxicity; Biomarkers; Breast cancer

Indexed keywords

ALDOSTERONE; ANTHRACYCLINE; BRAIN NATRIURETIC PEPTIDE; CATECHOLAMINE; CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; HEMOGLOBIN; TROPONIN I; TUMOR MARKER;

ADULT; AGED; ALDOSTERONE BLOOD LEVEL; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CARDIOTOXICITY; CLINICAL ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; ENZYME KINETICS; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE EJECTION FRACTION; HEMOGLOBIN BLOOD LEVEL; HUMAN; MALE; MASTECTOMY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY; SIDE EFFECT;

ADULT; AGED; ANTHRACYCLINES; BIOLOGICAL MARKERS; BREAST NEOPLASMS; CARDIOTOXINS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PHARMACOKINETICS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; STROKE VOLUME;

EID: 84864694032     PISSN: 15307905     EISSN: 15590259     Source Type: Journal    
DOI: 10.1007/s12012-011-9149-4     Document Type: Article

References (23)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). (2005). Effect of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. The Lancet, 365, 1687-1717.
2. Singal, P. K., & Iliskovic, N. (1995). Doxorubicin-induced car-diomyopathy. New England Journal of Medicine, 332, 1738-1743.
3. Von Hoff, D., Layard, M., Basa, P., Davis, H. L., Von Hoff, H. L., Rozencweig, M., et al. (1979). Risk factors for doxorubicin-induced congestive heart failure. Annals of Internal Medicine, 91, 710-717.
4. Ryberg, M., Nielsen, D., Skovsgaard, T., Hansen, J., Jensen, B. V., Dombernowsky, P. (1998). Epirubicin cardiotoxicity: An analysis of 469 patients with metastatic breast cancer. Journal of Clinical Oncology, 16, 3502-3508.
5. Praga, C., Trave, F., & Petroccione, A. (1991). Anthracycline-induced cardiotoxicity and its relevance in cancer treatment. In W. S. Nimmo & G. T. Tucker (Eds.), Clinical measurement in drug evaluation (pp 131-142). Boca Raton, FL: CRC Press.
6. Ganz, W. I., Sridhar, K. S., Ganz, S. S., Gonzales, R., Chakko, S., Serafini, A. (1996). Review of tests for monitoring doxorubicin-induced cardiomyopathy. Oncology, 53, 461-470.
7. Mitani, I., Jain, D., Joska, T. M., Burtness, B., Zaret, B. L. (2003). Doxurubicin cardiotoxicity: Prevention of congestive heart failure with serial function monitoring with equilibrium radionuclide angiocardiography in the current era. Journal of Nuclear Cardiology, 10, 132-139.
8. Feola, M., Garrone, O., Occelli, M., Francini, A., Biggi, A., Visconti, G., et al. (2011). Cardiotoxicity after anthracycline chemotherapy in breast carcinoma: Effects on left ventricular ejection fraction, troponin I and brain natriuretic peptide. International Journal of Cardiology, 148, 194-198.
9. Corbett, J. R., Akinboboye, O. O., Bacharach, S. L., Borer J. S., Botvinick, E. H., DePuey, E. G., et al. (2006). Equilibrium radionuclide angiocardiography. Journal of Nuclear Cardiology, 13, e56-e79.
10. De Nigris, F., Rienzo, M., Schiano, C., Fiorito, C., Casamassimi, A., Napoli, C. (2008). Prominent cardioprotective effects of third generation beta blocker nebivolol against anthracycline-induced cardiotoxicity using the model of isolated perfused rat heart. European Journal of Cancer, 44, 334-340.
11. Kalay, N., Basar, E., Ozdogru, I., Er, O., Cetinkaya, Y., Dogan, A., et al. (2006). Protective effects of carvedilol against anthra-cycline-induced cardiomyopathy. Journal of the American College of Cardiology, 48, 2258-2262.
12. Bien, S., Riad, A., Ritter, C. A., Gratz, M., Olshausen, F., Westermann, D., et al. (2007). The endothelin receptor blocker bosentan inhibits doxorubicin-induced cardiomyopathy. Cancer Research, 67, 10428-10435.
13. Cardinale, D., Colombo, A., Sandri, M. T., Lamantia, G., Colombo, N., Civelli, M., et al. (2006). Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation, 114, 2474-2481.
14. Cardinale, D., Colombo, A., Lamantia, G., Colombo, N., Civelli, M., De Gaicomi, G., et al. (2010). Anthracycline-induced car-diomyopathy: Clinical relevance and response to pharmacologic therapy. Journal of the American College of Cardiology, 55, 213-220.
15. van Dalen, E. C., Caron, H. N., Dickinson, H. O., & Kremer, L. C. (2008). Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database of Systematic Reviews (2), CD003917.
16. Lipshultz, S. E., Rifai, N., Sallan, S. E., Lipsitz, S. R., Dalton, V., Sacks, D. B., & Ottlinger, M. E. (1997). Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury. Circulation, 96, 2641-2648.
17. Cardinale, D., Sandri, M. T., Martinoni, A., Borghini, E., Civelli, M., Lamantia, G., et al. (2002). Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy. Annals of Oncology, 13, 710-715.
18. Cardinale, D., Sandri, M. T., Colombo, A., Colombo, N., Boeri, M., Lamantia, G., et al. (2004). Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation, 109, 2749-2754.
19. Shinohara, K., & Tanaka, K. R. (1980). The effects of adriamycin (doxorubicin HCl) on human red blood cells. Hemoglobin, 4, 735-745.
20. Misiti, F., Giardina, B., Mordente, A., & Clementi, M. E. (2003). The secondary alcohol and aglycone metabolites of doxorubicin alter metabolism of human erythrocytes. Brazilian Journal of Medical and Biological Research, 36, 1643-1651.
21. Catena, C., Colussi, G., Marzano, L., & Sechi, L. A. (2011). Aldosterone and the heart: From basic research to clinical evidence. Hormone and Metabolic Research [Epub ahead of print].
22. Suzuki, T., Hayashi, D., Yamazaki, T., et al. (1998). Elevated B-type natriuretic peptide levels after anthracycline administration. American Heart Journal, 136, 362-363.
23. Cheitlin, M. D., Armstrong, W. F., Aurigemma, G. P., Beller, G. A., Biermon, F. Z., Davis, J. l., et al. (2003). ACC/AHA/ASE 2003 guideline update for the clinical application of echocardi-ography: Summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology, 42, 954-970.